External validation of the Moroccan Arabic version of the European Organization for Research and Treatment of Cancer colorectal (CR29) module: Monocentric study

doi:10.5662/wjm.v13.i4.259

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 4

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5919)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-6) series.

Item

Count

PDF

172

WORD

HTML

1838

Tables (1-6)

600

Sum=2652

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

412

Download

1236

Sum=1648

Publishing Process of This Article

Item

Count

Browse

366

Download

1071

Sum=1437

Sep 20, 2023 (publication date) through Feb 26, 2026

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Methodol. Sep 20, 2023; 13(4): 259-271
Published online Sep 20, 2023. doi: 10.5662/wjm.v13.i4.259

External validation of the Moroccan Arabic version of the European Organization for Research and Treatment of Cancer colorectal (CR29) module: Monocentric study

Houda Bachri, Hajar Essangri, Nezha El Bahaoui, Amine Benkabbou, Raouf Mohsine, Anass Mohammed Majbar, Amine Souadka

Houda Bachri, Hajar Essangri, Nezha El Bahaoui, Amine Benkabbou, Raouf Mohsine, Anass Mohammed Majbar, Amine Souadka, Surgical Oncology Department, National Institute of Oncology, Mohammed Vth University in Rabat, Rabat 10100, Morocco

Hajar Essangri, Gynecology oncology Department, Royal London Hospital, Barts NHS Health, London SE18 6EY, United Kingdom

Author contributions: Souadka A and Bachri H have contributed to the conception and design of the study, acquisition of the data, the analysis and the interpretation of data; Souadka A, Bachri H and Essangri H wrote the first draft; El Bahaoui N, Majbar AM and Benkabbou A critically reviewed the draft for important intellectual content; Mohsine R was involved in revising critically the corrected manuscript and all authors read and gave the final approval of the version to be published.

Institutional review board statement: The Approval of the study protocol was obtained from the institutional ethics review board (number: 79/17) and all patients enrolled in the study provided a written, informed consent allowing the use of their data for clinical studies at the time of their initial visit.

Conflict-of-interest statement: The authors declare no conflict of interest.

Data sharing statement: Derived data supporting the findings of this study are available from the corresponding author a.souadka@um5r.ac.ma upon reasonable request.

Corresponding author: Amine Souadka, MD, PhD, Professor, Surgical Oncology Department, National Institute of Oncology, Mohammed Vth University in Rabat, Hay riad Souissi, Rabat 10100, Morocco. a.souadka@um5r.ac.ma

Received: April 22, 2023
Peer-review started: April 22, 2023
First decision: June 14, 2023
Revised: July 26, 2023
Accepted: September 1, 2023
Article in press: September 1, 2023
Published online: September 20, 2023
Processing time: 151 Days and 6 Hours

Abstract

BACKGROUND

Quality of life (QoL) outcomes are a focal endpoint of cancer treatment strategies.

AIM

To externally validate the Moroccan Arabic version of the European Organization for Research and Treatment of Cancer (EORTC) QoL Questionnaire (QLQ) for colorectal cancer (CRC) patients (CR29).

METHODS

Both Moroccan Arabic modules of QLQ-CR29 and QLQ-C30 were administered to Moroccan CRC. Psychometric properties were retested by measuring Cronbach’s alpha coefficient for reliability and Intraclass correlation coefficient (ICC) to examine test-retest reproducibility. The multitrait-scaling analysis was performed to demonstrate the validity of the instrument and known-groups comparison was used to test the score’s ability to discriminate between different groups of patients.

RESULTS

In total, 221 patients were included in our study and 34 patients completed the questionnaire twice. The Urinary Frequency scale and Stool Frequency scale had good internal consistency with alpha Cronbach coefficients of 0.79 and 0.83 respectively, while the same coefficients were moderately lower for the Blood and Mucus in Stool scale (0.61) and the Body Image scale (0.67). The ICCs ranged from 0.88 to 1 indicating good to excellent reproducibility. In multitrait scaling analyses, the criterion for item convergent and divergent validity was satisfactory. The known-group comparison showed statistically significant differences between patients according to age, gender, stoma status, tumor location, and radiotherapy.

CONCLUSION

The Moroccan Arabic version of the EORTC QLQ-CR29 is a valid and reliable tool that can be used safely for research and clinical purposes in Moroccan CRC patients.

Keywords: Rectal neoplasm; Colorectal cancer; Health-related quality of life; Patient reported outcome measures; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CR29; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30

Core Tip: Patient related outcomes such as quality of life (QoL) are a focal endpoint of cancer treatments strategies. Many QoL Questionnaire (QLQ) are not trully validated. We aim to externally validate the Moroccan Arabic version of the European Organization for Research and Treatment of Cancer QLQ CR29 on larger and more heterogenous population in order to affirm its validity and reliability in arabic colorectal cancer patients.